Hyper Vision Limited

Hyper Vision Limited Obtains a Second Round of Funding from China-based Venture Capitalists

Shenzhen / November 14, 2020 / — After successful human trials of the Hyprvue Headset, Hyper Vision Limited has announced it has received further funding from private equity investors.

The evolving company is in the advanced stages of its initial products human trials and hopes to make its Hyprvue device available to all healthcare facilities in the Asia Pacific area by mid-2022 and then globally by 2023.

Sources at the company have not revealed the amount raised in the funding.

Hyper Vision Limited has said the new investments would improve production and make the Hyprvue Headset more globally available and research and development into a new artificial intelligence product. The company held their cards close to their chest when asked about the latest product in development, only confirming it will be revealed in the upcoming months.

Chief Executive Officer of Hyper Vision Limited, Yan Jiang, said in a statement, “We are overwhelmed with this latest round of funding. It shows that our investors are just as excited as we are with our technology.”

Chief Executive Officer of Hyper Vision Limited, Yan Jiang, said in a statement, “We are overwhelmed with this latest round of funding. It shows that our investors are just as excited as we are with our technology.”

“By developing our own hardware, we were able to create a system that is tailored for orthopedic surgeons and avoid the limitations that come with modifying off-the-shelf AR glasses,” said Qian Wen, Chief Technological Officer, Hyper Vision Limited.

After the first reported successful knee replacement surgeries performed with HyprVue in July of this year, Hyper Vision Limited has confirmed that more successful operations have been completed using the augmented reality technology, including hip arthroplasties, shoulder arthroplasties, ankle joint fusions, and recently an ACL reconstructive surgery.

Hyper Vision Limited is changing the future of healthcare by utilizing advances in augmented reality and artificial intelligence technology.
Contact Us

Rongchao Center,
6003 Yitian Road,
Futian District, Shenzhen, China. 518000